19191 - Ph3 Nivo +/- Doce mPC 7DX

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)

Disease Types: Prostate,&nbs

Available at: {clinical_trial_location backspace="7"}19191 - Ph3 Nivo +/- Doce mPC 7DX, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}